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ABSTRACT 
Myostatin (MSTN) negatively regulates skeletal muscle growth by suppressing myoblast 
proliferation and muscle fiber hypertrophy. Effective suppression of MSTN leads to dramatic 
improvement of animal muscle growth. MSTN propeptide (MSTNpro) is a potent inhibitor of 
MSTN activity. Studies suggest that in some species like mice and rabbits, muscle fiber number 
is increasing during the early neonatal period. We postulated that enhancing muscle fiber 
hyperplasia of these animal species during early neonatal period might increase postnatal skeletal 
muscle growth of these animals. Therefore, the objective of this study was to examine the effect 
of neonatal administration of MSTNpro on skeletal muscle growth in mice. Recombinant 
truncated flatfish MSTNpro fused to mouse IgG Fc domain (fMSTNpro45-100mFc) was 
produced in Escherichia coli (E. coli) using pMAL-c5x expression vector and purified by the 
amylose and protein A affinity chromatography. About 7.52 mg of purified recombinant MBP-
fMSTNpro45-100mFc was obtained from 1 L culture. The MSTN-inhibitory capacity of the 
purified recombinant MSTNpro was similar to that of a commercial MSTNpro produced from 
eukaryotic cells in a pGL3-(CAGA)12-Luciferase repeater gene assay. In an oral administration 
study, eight female mice (4-month-old) were mated to two males (4-month-old), and the female 
mice were randomly divided into two groups: control and treatment. New-born pups in the 
treatment and control groups were fed with MBP-fMSTNpro45-100mFc (10 µg/g pup) and PBS, 
respectively, twice one day apart. The pups were weaned at 4 weeks, and their body weight were 
measured weekly for 7 weeks after weaning. At 11 weeks after weaning, animals were 
sacrificed, and gastrocnemius complex (gastrocnemius, plantaris and soleus) muscle and organ 
(heart, liver, spleen, kidney) samples were collected and weighed. Following the oral 
administration experiment, the same male and female mice were used for an intraperitoneal 
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administration study with the same experimental design. Newborn pups in the treatment and 
control groups were intraperitoneally injected MBP-fMSTNpro45-100mFc (10 µg/g pup) and 
PBS, respectively, on the first and second day after birth. At 10 weeks after weaning, mice were 
sacrificed for the muscle and organ weight. Either neonatal oral administration or intraperitoneal 
injection of MBP-fMSTNpro45-100mFc did not significantly affect body weight growth and 
gastrocnemius muscle and organ weights of mice. This result implies that the administration of 
MBP-fMSTNpro45-100mFc under early neonatal period did not enhance muscle hyperplasia in 
mice. However, this study did not examine either the transfer of recombinant MSTNpro into 
circulation or the muscle fiber number after the administration. Furthermore, dose-response was 
not examined. Further studies are needed to validate the potential of neonatal suppression of 
MSTN as a strategy to improve skeletal muscle growth of animals. 
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CHAPTER 1 
LITERATURE REVIEW 
1.1. Overview of skeletal muscle growth 
1.1.1. Prenatal growth of skeletal muscle  
Skeletal muscle of the vertebrate animals derives from somites, segments of paraxial 
mesoderm that form following an anterior–posterior progression on either side of the neural tube 
and notochord (Tajbakhsh and Buckingham, 1999). Specifically, the dorsal part of the somite, 
the dermo-myotome, gives rise to the overlying derm of the back and the skeletal muscles of the 
body and limbs (Buckingham et al., 2003). Myogenesis in all animals is directed, in part, by 
groups of transcription factors that orchestrate the processes of muscle differentiation (Baylies et 
al. 1998; Wigmore and Evans, 2002). In vertebrate skeletal muscles, these include myogenic 
regulatory factors, the basic helix-loop-helix proteins Myf5, MyoD, Myf4, and Myogenin, which 
play complementary roles in directing muscle development (Wigmore and Evans, 2002).  
First, muscle progenitor cells delaminate from the epithelium of the hypaxial 
dermomyotome and migrate into the limb ﬁeld, to the positions where the dorsal and ventral 
muscle masses will form initially (Christ and Ordahl, 1995). However, cells that migrate from 
the somite have not yet activated the myogenic determination genes and it is only when they 
reach the limb that they begin to express MyoD and Myf5 (Tajbakhsh and Buckingham, 1999). 
Before skeletal muscle forms, the muscle precursor cells, myoblasts, probably both before and 
after activation of Myf5 and MyoD, undergo extensive proliferation in the limb. Then myoblast 
proliferation is arrested and differentiates into myotube which depends on Myogenin and other 
differentiation factors like Mef2 (Buckingham et al., 2003). During this period, myotube 
formation occurs in two or three temporally distinct phases. The first wave of myotubes comes 
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from embryonic myoblasts, the second from fetal myoblasts, and they respectively give rise to 
the primary and secondary muscle fibers (Feldman and Stockdale, 1992). The first muscle fiber 
that appears is known as primary fiber, around which secondary fibers form at the time when 
innervation begins to be established (Ontell and Kozeka, 1984). Primary and secondary fibers 
can be distinguished morphologically and show some differences in muscle gene expression. It is 
generally believed that primary fibers mature to slow type I fibers in the adult but in entirely fast 
muscles, they give rise to fast type II fibers. The secondary fibers mostly mature to fast fibers in 
fast muscles and to either fast or slow fibers in the mixed muscles (Lefaucheur et al. 1995; Picard 
et al. 1995). Subsequently, the muscle masses undergo very extensive growth in the fetal period 
and postnatally (Buckingham et al., 2003). 
1.1.2. Postnatal growth of skeletal muscle 
Muscle fiber numbers are determined at around birth in most species of terrestrial 
vertebrates (Stickland, 1983). In bovines, the total number of muscle fibers is fixed from the end 
of the second trimester of gestation (180 days) (Picard et al. 1994; Gagnière et al. 1999). And the 
total number of fibers is considered to be established at around 95 d of gestation in pigs 
(Wigmore and Stickland, 1983). In birds, it is generally believed to be established before 
hatching (Rémignon et al., 1995). In less mature species such as the rabbit, the total number of 
fibers is determined during the first month after birth (Nougues, 1972). In the 1-day old rat 
neonate, fusing myoblasts and oriented myotubes appeared between the mononucleated cells 
(Oron, 1990). Fusion of myoblast to myotubes took place during the first day after birth (Oron, 
1990). Therefore, although in most vertebrates, postnatal muscle growth is mostly due to 
hypertrophy (muscle fiber size increase), hyperplasia (muscle fiber number increase) may still 
occur in the early neonatal stage in some altricial species.  
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In birds and mammals, the large postnatal increase in muscle mass is achieved by the 
hypertrophy of the existing muscle fibers, and satellite cell (SC) fusion with the fibers occurs 
during the hypertrophy process (Grounds, 1991). SCs were first identified in 1961 (Mauro), 
located between the sarcolemma of the myofiber and the basal membrane (BM) (Mauro, 1961; 
Muir et al. 1965). They can be activated by myotrauma or excise, proliferate, self-renew, and 
finally differentiate into multinucleated myofibers (Hurme and Kalimo, 1992; Pavlath and 
Horsley, 2003; Charge ́ and Rudnicki, 2004; Shi and Garry, 2006). In the neonate, SCs 
proliferate actively, adding nuclei to fibers (Moss and Leblond, 1971), while in the adult, they 
are mitotically quiescent and only become active in response to an insult or injury to the muscle 
(Campion, 1984).  
In healthy adult animals, muscle hypertrophy is also achieved by controlling the balance 
of protein turnover. All muscle fibers are constantly synthesizing and degrading myofibrillar 
proteins, and the balance between these two processes determines whether protein content 
increases, decreases or remains constant. During growth, the rate of protein synthesis is greater 
than the rate of protein degradation, resulting in accumulation of proteins (Tipton and Wolfe, 
2001). Increases in myofibril length and diameter occur as muscle fibers grow. Myofibrils grow 
in length by adding new sarcomeres at the ends of myofibrils and increase in diameter by adding 
new thick and thin filaments to the periphery of existing myofibrils. Consequently, as proteins 
like myosin and actin are synthesized on polyribosomes, they assemble into new filaments, and 
these new filaments associate with existing filaments in myofibrils. The new filaments are added 
to the surface of myofibrils, and they are integrated into the structure. 
Degradation of muscle proteins is also a critical process in muscle growth, highly 
regulated and balanced with protein synthesis. It is mediated by proteolytic enzymes (Sugden 
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and Fuller, 1991), like calpain, caspase, lysosomal protease and the ubiquitin-dependent 
proteasome. Calpains are calcium-activated cysteine proteases. In vitro, calpains initiate 
digestion of individual myofibrillar proteins, including desmin, C-protein and tropomyosin 
(Huang and Forsberg, 1998). Calpains are also activated in conditions of muscle wasting, 
including Duchenne muscular dystrophy (Arahata and Sugita, 1989) and fasting (Arakawa et al., 
1983). Calpains play a significant role in myofibrillar protein degradation, especially in the 
disassembly of the myofibril during early stages of turnover (Goll et al., 1989). The proteasome 
is also involved in myofibrillar protein degradation. The proteasome, a large, ubiquitous ATP- 
and ubiquitin-dependent proteolytic system, is able to degrade actin and myosin (Solomon and 
Goldberg, 1996). Studies also show that these two kinds of protease work synergistically in 
muscle protein degradation. Calpain 3, the muscle-specific calpain, contributes to protein 
ubiquitination (Kramerova et al., 2005), and calpain activation in myotubes increases proteasome 
enzyme activity (Menconi et al., 2004). The caspases, cysteine-aspartic proteases, are a family of 
protease enzymes playing essential roles in programmed cell death. A study indicated that the 
initial step in progressive loss of muscle protein in acute diabetes and renal insufficiency is 
activation of caspase-3, which cleaves actomyosin to its constituent proteins and fragments of 
these proteins, and then the resulting substrates are finally degraded in the ubiquitin-dependent 
proteasome system (Lee et al., 2004). 
1.2. Regulators of skeletal muscle growth 
1.2.1. The IGF1/PI3K/Akt and PI3K/Akt/mTOR hypertrophy signaling pathways 
Muscle hypertrophy can be induced by multiple anabolic stimuli – among the most 
studied of which is insulin-like growth factor 1 (IGF1) (Bodine et al., 2001b; Rommel et al., 
2001). Signaling via IGF1 is mediated first by IGF1 ligand binding to its receptor, the tyrosine 
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kinase IGF1 receptor (IGF1R). This binding induces trans-phosphorylation of the dimeric 
receptor, and the resultant phosphorylated tyrosines create a docking site for the recruitment of 
the Insulin Receptor Substrate 1 (IRS1) (Bohni et al., 1999). The IGF1 pathway can be 
inactivated after prolonged insulin stimulation by targeting IRS1 for ubiquitin-mediated 
degradation (Tzatsos and Kandror, 2006; Xu et al., 2008). Muscle-specific overexpression in 
transgenic mice of an IGF1 isoform locally expressed in skeletal muscle results in muscle 
hypertrophy (Musaro et al., 2001). Akt activation is induced by IGF1 and insulin through the 
generation of phosphatidylinositol-3,4,5- triphosphates produced by phosphatidylinositol 3 
kinase (PI3K). The role of Akt in muscle growth was first suggested by the finding that an active 
Ras mutant could promote muscle growth through selective activation of the Akt pathway by 
PI3K (Murgia et al., 2000).  
The kinase mTOR (mammalian target of rapamycin) has emerged as a key regulator of 
cell growth that integrates signals from growth factors, nutrients, and energy status to control 
protein synthesis and other cell functions (Hay and Sonenberg, 2004; Teleman et al., 2008). 
mTOR is part of two multiprotein complexes: mTORC1, which contains raptor and is rapamycin 
sensitive, is required for signaling to S6K and 4EBP1, whereas mTORC2, which contains rictor, 
is required for signaling to Akt-FoxO. The effect of mTOR on the translation machinery and 
protein synthesis is mediated by TORC1-dependent phosphorylation of the ribosomal protein S6 
kinases (S6K1 and 2) and of 4E-BP1, a repressor of the cap-binding protein eIF4E (Sandri, 
2008). The activation of mTOR by Akt is indirect and involves the phosphorylation and 
inhibition by Akt of tuberous sclerosis 2 (TSC2). The role of mTOR in muscle growth was 
demonstrated by in vivo studies showing that a mTOR inhibitor, rapamycin, blocked overload 
hypertrophy and regenerating muscle growth (Bodine et al., 2001; Pallafacchina et al., 2002). 
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The study found out that the activation of the Akt/mTOR pathway and its downstream targets, 
p70S6K and 4E-BP1, is requisitely involved in regulating skeletal muscle fiber size, and that 
activation of the Akt/mTOR pathway can oppose muscle atrophy induced by disuse (Bodine et 
al., 2001). The results suggest that activation of mTOR via PI3K/Akt serves as a crucial regulator 
of muscle fiber growth. A study showed the motor neuron activity on skeletal muscle growth 
could regenerate muscle dependent on the PI3K/Akt/mTOR pathway (Pallafacchina et al., 2002).  
These studies emphasized the important role that PI3K/Akt/mTOR pathway plays in 
regulating skeletal muscle hypertrophy during postnatal development of animals. 
1.2.2. MuRF1 and MAFbx mediated induction of muscle atrophy 
In contrast to hypertrophy, skeletal muscle atrophy is characterized by a shift toward 
protein degradation, resulting from cachectic stimuli such as inflammatory cytokines and 
glucocorticoids. Proteolysis, as observed in atrophy, has been shown to occur in part due to the 
activation of ubiquitin-mediated proteasomal degradation (Mitch & Goldberg, 1996). Multiple 
models of muscle atrophy, including denervation, high-dose dexamethasone treatment, treatment 
with inflammatory cytokines, and simple immobilization, all induce transcriptional upregulation 
of MuRF1 and MAFbx (also called atrogin-1), genes that encode for E3 ubiquitin ligases 
(Bodine et al., 2001a; Gomes et al., 2001). A double knockout study also demonstrated that in 
animals there was a profound loss of type II fibers caused by MuRF1/MuRF2 interactions 
(Moriscot et al., 2010). MAFbx has been convincingly shown to be an E3 ligase for eIF3-f, a 
protein initiation factor (Li, 2007). Also, MAFbx activity results in muscle atrophy through the 
downregulation of protein synthesis. Activation of Akt can in turn inhibit the transcriptional 
upregulation of MAFbx and MuRF1 normally seen during atrophy (Ruegg and Glass, 2011). 
Their normal upregulation was demonstrated to require the FOXO (also known as Forkhead) 
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family of transcription factors (Sandri et al., 2004; Stitt et al., 2004). FOXO transcription factors 
are excluded from the nucleus when phosphorylated by Akt and translocate to the nucleus upon 
dephosphorylation (Brunet et al., 1999). The translocation and activity of FOXO transcription 
factors are required for upregulation of MuRF1 and MAFbx. In the case of FOXO3, the 
activation was demonstrated to be sufficient to induce atrophy (Mammucari et al., 2007; Zhao et 
al., 2007), a finding that was subsequently supported by the transgenic expression of FOXO1, 
which also resulted in an atrophic phenotype (McLoughlin et al., 2009; Southgate et al., 2007). 
1.3. Myostatin 
1.3.1. Physiology and biochemistry of myostatin 
Myostatin (MSTN), also known as growth differentiation factor 8 (GDF-8), is a 
transforming growth factor- (TGF-) family member and plays an essential role in regulating 
skeletal muscle growth (McPherron et al., 1997). It is encoded by the Mstn gene. MSTN is 
expressed initially in the myotome compartment of developing somites and continues to be 
expressed in the myogenic lineage throughout development and in adult animals. Mice carrying a 
targeted deletion of the Mstn gene have a dramatic and widespread increase in skeletal muscle 
mass. The MSTN sequence has been highly conserved through evolution (McPherron and Lee, 
1997). The human, rat, murine, porcine, turkey, and chicken MSTN sequences are similar in the 
biologically active C-terminal portion of the molecule (McPherron and Lee, 1997; Grobet et al., 
1997; Kambadur et al., 1997; Grobet et al., 1998). MSTN is translated as a precursor protein 
(proMSTN) composed of a signal sequence, an N-terminal propeptide domain and a C-terminal 
mature (active) domain (McPherron et al., 1997; Wolfman et al., 2003). After removal of the 
signal peptide, the proMSTN forms a disulfide-linked homodimer and is proteolytically 
processed at a conserved RXRR site by the furin family of proprotein convertases to generate 
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propeptide and mature MSTN (Lee and McPherron, 2001; Thies et al., 2001). After cleavage, the 
disulfide-linked homodimer of mature MSTN is complexed with propeptide through non-
covalent bond, inhibiting MSTN activity by remaining in a latent/inactive state (Hill et al., 2002; 
Thies et al., 2001; Zimmers et al., 2002). MSTN is activated from the latent state through 
cleavage of MSTNpro by members of the bone morphogenetic proteins-1/tolloid (BMP-1/TLD) 
of metalloproteinases (Wolfeman et al., 2003; Lee, 2008). Hence, like other TGF- family 
members, MSTN is secreted and proteolytically processed as the mature form of MSTN 
(McPherron et al., 1997).  
MSTN binds to Activin Receptor II A or B (ActRIIA or B) and Activin-Like Kinase-4 or 
5 (ALK-4 or 5) (McPherron et al., 1997). The receptor binding initiates intracellular signaling 
via phosphorylation and activation of the transcription factors Smad2 and 3, which translocate to 
the nucleus and activate target genes (McCroskery et al., 2003; Rebbapragada et al., 2003). In 
skeletal muscle, MSTN negatively regulates Akt signaling (Sartori et al., 2009; Trendelenburg et 
al., 2009). Moreover, Smad2/3 inhibition promotes muscle hypertrophy partially dependent on 
mammalian target of rapamycin (mTOR) signaling. Thus, MSTN and Akt pathways cross-talk at 
different levels. These findings point to MSTN inhibitors as potential therapeutics to promote 
muscle growth during rehabilitation, especially when they are combined with IGF-1-Akt 
activators (Sartori et al., 2009). Furthermore, it has been shown that inflammatory signaling, 
downstream of cytokine activation, induces endogenous expression of the TGF- family member 
activin, demonstrating an important interaction of cytokine and TGF- signaling, revealing a 
new mechanism by which cytokines affect skeletal muscle and establishing the physiologic 
relevance of this pathway in the impaired regeneration seen in sarcopenia (Trendelenburg et al., 
2012).  
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MSTN knockout mice have two- to three-fold greater muscle mass than their wild type 
littermates. The increased muscle mass is the result of fiber hypertrophy and hyperplasia 
(McPherron et al., 1997). In addition, the MSTN knockout mice accumulate less fat than their 
wild type littermates (McPherron and Lee, 2002; Lin et al., 2002), which may be a secondary 
consequence of increased muscle mass since a similar effect is seen in other genetic models of 
muscle hypertrophy (Musaro et al., 2001; Sutrave et al., 1990). Aside from having increased 
muscle and decreased fat, the MSTN knockout mice appear normal and healthy.  
A similar result was also found in cattle (Grobet et al. 1997; Kambadur et al. 1997; 
McPherron and Lee, 1997), sheep (Clop et al., 2006), dog (Mosher et al., 2007), and human 
(Schuelke et al., 2004) when mutations occur in the Mstn gene. In 2015, researchers successfully 
generated MSTN-mutant Meishan pigs using Zinc Finger Nuclease technology in combination 
with somatic cell nucleus transfer. The MSTN-mutant pigs developed and grew normally and 
increased growth performance after 6 months of age with dramatic skeletal muscle mass, 
producing a significant amount of carcass lean tissue and less body fat (Qian et al., 2015). 
1.3.2. Myostatin inhibition 
Follistatin (FST) is an autocrine, secretory glycoprotein that plays a prominent role in 
mammalian prenatal and postnatal development. Two FST proteins with molecular weights of 32 
and 35 kDa were first discovered in 1987 (Ueno et al., 1987). FST is a TGF-β binding protein, 
and the biological activity of FST encompasses multiple organ systems, including bone, skeletal 
muscle, and liver (Lin et al., 2003). MSTN can be regulated by FST, which binds the C-terminal 
dimer and inhibits its ability to bind to receptors. The release of the C-terminal dimer from these 
inhibitory proteins allows MSTN to signal through activin type II receptors (Lee and McPherron, 
1997).  
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A gene therapy approach to MSTN inhibition represents an important consideration for 
patients with muscle disease. In contrast to pharmacologic administration of MSTN inhibitors 
such as neutralizing antibodies (Bogdanovich et al., 2002), recombinant pharmacologic agents 
like MSTNpro (Bogdanovich et al., 2005) or drugs such as trichostatin A (Minetti et al., 2006), 
gene therapy offers the convenience of a single administration of vector carrying MSTN-
inhibiting gene with persistent expression for many years (Mueller and Flotte, 2008).  
MSTNpro (37 kDa with glycosylation), the N-terminal part of unprocessed MSTN, has 
been shown to suppress MSTN bioactivity by inhibiting MSTN binding to its membrane receptor 
(Thies et al. 2001). Overexpression or administration of MSTNPro has been shown to enhance 
skeletal muscle growth in laboratory animal species (Hu et al. 2010; Lee and McPherron 1999, 
2001; Li et al. 2010; Matsakas et al. 2009; Pirottin et al. 2005; Wolfman et al. 2003; Yang et al. 
2001). Transgenic mice overexpressing MSTNpro showed a phenotype with enhanced muscle 
mass (Yang et al. 2001; Lee and McPherron, 2001; Pirottin et al., 2005). In dogs, MSTNpro 
overexpression via hydrodynamic limb vein injection of adeno-associated virus vector carrying 
the canine MSTNpro gene induced muscle hypertrophy (Qiao et al., 2009). These results showed 
that MSTNpro is capable of enhancing muscle growth by blockage of MSTN activity in vivo. 
Inhibition of MSTN function through its propeptide may also have applications to improve the 
growth performance of agriculturally important animals, such as pigs. The administration of 
mutated porcine MSTNpro to neonatal mice resulted in significant increase in growth 
performance (Li et al., 2010), suggesting that pharmacological inhibition of MSTN is also an 
effective way to improve skeletal muscle growth of animals. Moreover, transgenic mice 
expressing porcine MSTNpro exhibit a significant increase in body, carcass weight, and limb 
weight and myofiber size (Wang et al., 2013). The transgenic mice were healthy without 
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showing any defect. A study also showed that the administration of metalloproteinase-resistant 
mutant form of MSTNPro could significantly enhance skeletal muscle growth in mice (Wolfman 
et al. 2003). Moreover, a study has shown that both fish MSTN prodomain and FST are able to 
inhibit fish MSTN activity in vitro, suggesting that a similar mechanism is operating in fish as in 
mammals (Rebhan and Funkenstein, 2008). These results point to the potential prospects of 
using the two MSTN binding proteins to inhibit MSTN activity in vivo for enhancing muscle 
growth. A region of human MSTNpro containing residues 42–99 fully suppressed MSTN 
activity in co-transfection experiments. The scientists designed a series of truncation and deletion 
constructs of the full-length human MSTNpro including 239 amino acid residues. Each construct 
was co-transfected with a TGF-β-sensitive Smad-responsive luciferase reporter gene into 
HEK293 human embryonic kidney cells. Expression of the full-length MSTNpro-Fc fusion 
protein resulted in a significant reduction of MSTN-induced transcriptional activity. Then it was 
testified that co-transfection of each truncated MSTNpro-Fc fusion protein suppressed luciferase 
activity in a region-specific manner (Ohsawa et al., 2015). Compared with full-length MSTNpro, 
the N-terminal of the propeptide 42-99 showed almost a full capacity (98.1%) for inhibition of 
MSTN-induced transcriptional activity. They also identified the inhibitory core of MSTNpro 
consisting of 29 amino acid residues. They also demonstrated for the first time that the inhibitory 
core of the MSTNpro could interact with the type I and II receptors as well as the ligand by in 
vitro experiments. Similarly, a synthetic mouse MSTNpro containing residues 45–68 was 
effective in suppressing MSTN activity in mdx mice (Takayama et al., 2015). Also, it is shown 
that maltose binding protein (MBP)-fused flatfish MSTN1pro region consisting of residues 45–
100 had the same MSTN inhibitory potency as the MBP-fused full sequence flatfish MSTN1pro 
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(Lee et al., 2016), suggesting that partial sequences of MSTNpro would be sufficient to maintain 
the full MSTN-inhibitory capacity.  
Antibodies against MSTN has also been used to suppress MSTN activity in many studies. 
Blockade of endogenous MSTN by using intraperitoneal injections of blocking antibodies for 
three months resulted in an increase in body weight, muscle mass, muscle size and absolute 
muscle strength in mdx mouse muscle along with a significant decrease in muscle degeneration 
and concentrations of serum creatine kinase (Bogdanovich et a., 2002). The functional 
improvement of dystrophic muscle by MSTN blockade provides a pharmacological strategy for 
the treatment of diseases associated with muscle wasting such as DMD. In a study, female mice 
were induced to produce MSTN antibody by immunization with synthetic MSTN peptide prior 
to mating with male mice to examine the effect of active immunization on offspring growth and 
body composition (Liang et al., 2007). MSTN antibody was detected in both immunized female 
mice and their 8-week-old offspring. The growth performance of offspring from the MSTN 
antibody-induced group was higher than that from the control group at 8 weeks of age, 
suggesting that the induction of maternal MSTN antibody enhances the growth performance of 
offspring. In a 2006 study, researchers produced a monoclonal anti-MSTN antibody to examine 
the effects of in ovo administration of the antibody on post-hatch broiler growth and muscle 
mass. Eggs were injected once with monoclonal anti-MSTN antibody. Broilers from eggs that 
had the antibody injected into the yolk had significantly heavier body and muscle mass than the 
controls in both male and female birds. The results of this study indicated that 
immunoneutralization of MSTN during embryonic development is a potential means to improve 
growth potential of broilers (Kim et al., 2006). In another study, polyclonal antibodies having an 
affinity to chicken MSTNpro was produced , and the effect of in ovo administration of the 
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antibodies on post-hatch chicken growth and muscle mass was examined (Kim et al., 2007). The 
administration suppressed the post-hatch growth of broilers along with the decrease in muscle 
weight, indicating that MSTN activity was probably elevated by the binding of the antibody to 
the propeptide.  
Treatment with an anti-MSTN antibody (ATA 842) for 4 weeks reversed age-associated 
sarcopenia with increased muscle strength, reduced intramuscular triglyceride content, and 
improved muscle insulin sensitivity in old mice (Camporez et al., 2016). A recent study 
demonstrated that a potent anti-MSTN antibody, mRK35 and its clinical analog, domagrozumab, 
were able to induce muscle anabolic activity in both rodents, including the mdx mouse model of 
DMD, and non-human primates (Andre et al., 2017). Specific MSTN antagonism with the 
human antibody REGN1033 could enhance muscle mass and function in young and aged mice, 
showing beneficial effects of MSTN antagonism in models of skeletal muscle atrophy (Latres et 
al., 2015). 
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Chapter 2 
The effect of neonatal administration of recombinant myostatin propeptide on 
skeletal muscle growth in mice 
2.1. Abstract  
Myostatin (MSTN) negatively regulates skeletal muscle growth by suppressing myoblast 
proliferation and muscle fiber hypertrophy. Effective suppression of MSTN leads to dramatic 
improvement of animal muscle growth. MSTN propeptide (MSTNpro) is a potent inhibitor of 
MSTN activity. Studies suggest that in some species like mice and rabbits, muscle fiber number 
is increasing during the early neonatal period. We postulated that enhancing muscle fiber 
hyperplasia of these animal species during early neonatal period might increase postnatal skeletal 
muscle growth of these animals. Therefore, the objective of this study was to examine the effect 
of neonatal administration of MSTNpro on skeletal muscle growth in mice. Recombinant 
truncated flatfish MSTNpro fused to mouse IgG Fc domain (fMSTNpro45-100mFc) was 
produced in Escherichia coli (E. coli) using pMAL-c5x expression vector and purified by the 
amylose and protein A affinity chromatography. About 7.52 mg of purified recombinant MBP-
fMSTNpro45-100mFc was obtained from 1 L culture. The MSTN-inhibitory capacity of the 
purified recombinant MSTNpro was similar to that of a commercial MSTNpro produced from 
eukaryotic cells in a pGL3-(CAGA)12-Luciferase repeater gene assay. In an oral administration 
study, eight female mice (4-month-old) were mated to two males (4-month-old), and the female 
mice were randomly divided into two groups: control and treatment. New-born pups in the 
treatment and control groups were fed with MBP-fMSTNpro45-100mFc (10 µg/g pup) and PBS, 
respectively, twice one day apart. The pups were weaned at 4 weeks, and their body weight were 
measured weekly for 7 weeks after weaning. At 11 weeks after weaning, animals were 
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sacrificed, and gastrocnemius complex (gastrocnemius, plantaris and soleus) muscle and organ 
(heart, liver, spleen, kidney) samples were collected and weighed. Following the oral 
administration experiment, the same male and female mice were used for an intraperitoneal 
administration study with the same experimental design. Newborn pups in the treatment and 
control groups were intraperitoneally injected MBP-fMSTNpro45-100mFc (10 µg/g pup) and 
PBS, respectively, on the first and second day after birth. At 10 weeks after weaning, mice were 
sacrificed for the muscle and organ weight. Either neonatal oral administration or intraperitoneal 
injection of MBP-fMSTNpro45-100mFc did not significantly affect body weight growth and 
gastrocnemius muscle and organ weights of mice. This result implies that the administration of 
MBP-fMSTNpro45-100mFc under early neonatal period did not enhance muscle hyperplasia in 
mice. However, this study did not examine either the transfer of recombinant MSTNpro into 
circulation or the muscle fiber number after the administration. Furthermore, dose-response was 
not examined. Further studies are needed to validate the potential of neonatal suppression of 
MSTN as a strategy to improve skeletal muscle growth of animals. 
2.2. Introduction 
MSTN is a transforming growth factor- family member and acts as a negative regulator 
of skeletal muscle mass. MSTN is expressed initially in the developing somites and continues to 
be expressed in the myogenic lineage throughout development and in adult animals. Mice 
carrying a targeted deletion of the MSTN gene have a dramatic and widespread increase in 
skeletal muscle mass (Lee and McPherron, 1997), which indicates that suppression of MSTN 
activity can enhance animal skeletal muscle growth. MSTNpro is an effective inhibitor of MSTN 
and potentially an agent for improving muscle growth of animals. Overexpression or 
administration of MSTNPro has been demonstrated to enhance skeletal muscle growth in some 
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laboratory animals (Hu et al., 2010; Lee and McPherron, 1999). Using maltose binding protein 
(MBP) as a fusion partner,  bioactive MSTNpro was produced in soluble forms in an E. coli 
system (Lee et al., 2011; Haq et al., 2013), allowing an economic production of large quantity of 
an MSTN-inhibitory agent. Moreover, recent studies have shown that MBP-fused flatfish 
MSTN1 propeptide consisting of residues 45–100 is sufficient to maintain the full MSTN-
inhibitory activity in a pGL3-(CAGA)12-luciferase reporter assay (Lee et al., 2016), 
demonstrating the potential of the recombinant protein as an agent to improve skeletal muscle 
growth of animals via suppression of MSTN activity in vivo.  
Postnatal skeletal muscle mass is determined by the embryonic muscle fiber formation 
and postnatal muscle hypertrophy. In most species of terrestrial vertebrates, muscle fiber number 
is determined at around birth (Stickland, 1983). In bovines, total muscle fiber number is fixed 
from the end of the second trimester of gestation (180 days) (Picard et al. 1994; Gagnière et al. 
1999). The total number of fibers is considered to be established at around 95 d of gestation in 
pigs (Wigmore and Stickland, 1983). However, studies have indicated that muscle hyperplasia 
occurs during the early neonatl period in some altricial species, such as mice and rabbits 
(Nougues, 1972).  The total fiber number in a given muscle have a permanent effect on the 
postnatal growth of muscles (Hegarty and Allen, 1978; Powell and Aberle, 1981; Wigmore and 
Stickland, 1983), suggesting that enhancing myoblast proliferation during the neonatal period of 
these animal species would increase the muscle mass during the postnatal growth period. Many 
studies have shown that MSTN suppresses myoblast proliferation (Ríos et al., 2001; Rı́os et al., 
2002; Seiliez et al., 2012). It is, thus, hypothesized that neonatal suppression of MSTN would 
increase muscle hyperplasia, leading to increased postnatal skeletal muscle growth in mice. 
Therefore, the objectives of the study were: (1) to express and purify a bioactive MSTNpro 
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protein in E. coli; (2) to investigate if the neonatal administration of MSTNPro affect  postnatal 
muscle growth in mice.  
2.3. Materials and Methods 
2.3.1. Construction of expression vectors  
An expression vector of mouse IgG Fc domain (mFc)-fused flatfish MSTN-1 propeptide 
containing amino acid sequences 45-100 (fMSTNpro45-100mFc) was previously constructed in 
Dr. Kim’s laboratory. Gibson assembly cloning method was used to insert the fMSTNpro45-100 
and mFc fragments into the XmnI site of pMAL-c5x expression vector (New England Biolab, 
MA, USA). To produce DNA fragment of fMSTNpro45-100 for Gibson assembly cloning, PCR 
was performed using the cDNA of full sequence flatfish MSTNpro (Lee et al., 2016) as a 
template. Q5 High-Fidelity DNA polymerase (New England Biolabs, MA, USA) was used with 
overlapping primer sets (Table 1). Mouse Fc cDNA was commercially synthesized with codon 
optimization and subcloned into a pUC57 cloning vector (GenScript, PA, USA). Mouse Fc 
fragments for Gibson cloning were produced by PCR with overlapping primer sets (Table 1) 
using the mouse Fc-pUC57 plasmid as a template. The overlapping primer sets were designed to 
contain G4S (GGTGGTGGTGGTTCT) linker between MSTNpro and Fc fragments. Each 
Gibson assembly reaction (New England Biolabs, MA, USA) contained approximately 100 ng of 
inserts and 50 ng of the XmnI-linearized pMAL-c5x vector, and incubated at 50°C for 30 min. 
After the assembly reaction, the reaction mixture was transformed into NEB 5α competent E. 
coli strain (New England Biolabs). After overnight growth at 37°C, the pMAL-c5x-fMSTNpro45-
100mFC plasmid was extracted to confirm correct insertion by colony PCR across the assembly 
junctions or by DNA sequence analysis. E. coli strain of K12TB1 (New England Biolab, MA, 
USA) was transformed with the expression construct by the heat-shock method and spread on 
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Luria-Bertani (LB) (1.2% tryptone, 0.6% yeast extract and 0.8% NaCl, 0.2% glucose) agar plates 
containing 50 μg/mL ampicillin.  
2.3.2. Expression of MBP-fMSTNpro45-100mFc fusion proteins in E. coli 
The transformed E. coli were spread on Luria-Bertani (LB) (1.0% tryptone, 0.5% yeast 
extract and 0.5% NaCl) agar plates containing 100 µg/ml ampicillin. Selected colonies were used 
to inoculate 5 mL LB medium containing 0.2% glucose and 100 µg/ml ampicillin for overnight 
growth at 37°C with vigorous shaking. The 5 mL cultures were used to inoculate 25 mL LB 
medium containing 0.2% glucose and 100 µg/ml ampicillin, and cells were grown to an OD600 
of 0.6–0.8. To induce the soluble expressions of MBP-fMSTNpro45-100mFc proteins, 
isopropyl-β-D-thiogalactoside (IPTG) was added to the cultures to a final concentration of 0.5 
mM, and then the cultures were grown at room temperature for 4, 6, 8, 10 and 12 hrs under 
vigorous shaking. SDS-PAGE analysis of the cell cultures was performed to confirm the 
optimum expression time of the recombinant protein. The culture induced for 6 hrs expressed the 
highest quantity of the fusion protein sized at 75 kDa, thus 6 h induction time was selected for 
large-scale expressions (1 L). Finally, truncated forms of flatfish MSTN 1 prodomain 
(fMSTNpro45-100) fused with mouse Fc domain at C-terminal side (MBP-fMSTNpro45-
100mFc) was obtained. 
2.3.3. Amylose-affinity chromatography of soluble MBP-fMSTNpro45-100mFc proteins 
After induction, the cell pellets were harvested by centrifugation at 4,000 g for 10 mins at 
4°C. Each gram (wet weight) of cell pellets was resuspended in 5 ml of column buffer (20 mM 
Tris, 200 mM NaCl, 1 mM EDTA, pH 7.5). The resuspended cell solution was frozen at -20 °C 
overnight. After thawing in cold water, the cells were added lysozyme and DNAse and then 
lysed by sonication in short pulses of 15 seconds for 15 min in ice-water bath. The cell lysates 
 19 
were then centrifuged at 20,000 g for 10 mins at 4°C. For each sample, the soluble fraction was 
collected and the same volume of column buffer was used to resuspend the insoluble fraction. 
SDS-PAGE analysis of the cell lysates, soluble, and insoluble fractions was performed to verify 
the soluble expression of the MBP-fMSTNpro45-100mFc proteins. The soluble fractions were 
subjected to amylose resin (New England BioLabs, MA, USA) affinity chromatography 
following the procedure described previously (Lee et al., 2012). Fractions were analyzed by 
SDS-PAGE to examine and characterize the purified proteins. 
2.3.4. Protein A affinity chromatography of amylose resin affinity-purified MBP-
fMSTNpro45-100mFc proteins 
After amylose affinity chromatography, eluted fractions containing MBP-fMSTNpro45-
100mFc proteins with high OD (OD>1.0) and eluted fractions with low OD (0.1-1.0) were 
pooled separately. The high OD collection and low OD collection were then subjected to protein 
A (Bio-Rad Laboratories, Inc., CA, USA) affinity chromatography following the procedure 
described previously (Hober et al., 2007). Fractions were analyzed by SDS-PAGE to examine 
and characterize the purified proteins. 
2.3.5. Protein assay 
Protein concentration was determined by the Modified Lowry Protein Assay (Thermo 
Scientific, CA, USA), using bovine serum albumin as a standard. 
2.3.6. SDS-PAGE 
SDS-PAGE was performed with 12.5% polyacrylamide gels. Samples were mixed with 
loading buffer containing 1.0 % β-mercaptoethanol. Protein bands were visualized by Coomassie 
brilliant blue staining after electrophoresis. 
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2.3.7. Bioactivity test for MBP-fMSTNpro45-100mFc proteins using the pGL3-(CAGA)12-
Luciferase reporter assay 
As described previously (Lee et al., 2016), capacities of MBP-fMSTNpro45-100mFc 
proteins to inhibit MSTN activities in vitro were measured using the pGL3-(CAGA)12-firefly 
luciferase reporter assay in HEK293 cells stably expressing (CAGA)12-luciferase gene construct. 
Cells  in DMEM with 10% fetal calf serum, penicillin-streptomycin plus fungizone were seeded 
in a 96-well culture plate (40,000 cells/well, 100 µL) and grown for 24 hrs at 37˚C with 5% 
CO2. One nM of MSTN (R&D Systems) plus various concentrations of commercial porcine 
MSTNpro (R&D Systems) or MBP-fMSTNpro45-100mFc in DMEM without serum were added 
to each well after removing the medium and incubated for 24 hrs. Luminescence was measured 
using Veritas microplate luminometer (Turner Biosystems Inc., CA, USA) after adding Bright-
Glo luminescence substrate (Promega, Madison, WI, USA). The % inhibition of MSTN activity 
was calculated by the following formula: % inhibition = (luminescence at 1 nM MSTN—
luminescence at each ligand concentration) *100/(luminescence at 1 nM MSTN– luminescence 
at 0 nM MSTN). The MSTN-inhibitory activities were analyzed by regression analysis using 
Prism 7 program (GraphPad, San Diego, CA). To examine the differences in MSTN-inhibitory 
capacity of the proteins, IC50 (ligand concentration inhibiting 50% of MSTN activity) values 
were estimated using a non-linear regression model defining dose response curve. The equation 
for the model was: Y = Bottom + (Top–Bottom)/ (1 + 10^(X–LogIC50)). Y is % inhibition, 
Bottom is the lowest value of % inhibition, Top is the highest value of % inhibition, and X is 
Log ligand concentration. IC50 values were analyzed by ANOVA (Analysis of Variance) using 
the same program. 
2.3.8. Animal experiments 
 21 
Oral administration of MBP-fMSTNpro45-100mFc to neonatal mice 
All of the procedures of animal care and experiments were approved by IACUC , 
University of Hawaii at Manoa (protocol No. 16-2319-2). Eight female (4-month-old) and two 
male (4-month-old) B6SJLF1/J mice were housed in Small Animal Facility at 12 hr/12 hr light-
dark cycles. Mice were fed with commercial rodent diet with clean water ad libitum. Four female 
mice were mated to each male, and the female mice were randomly divided into two groups: 
control and treatment. New-born pups in the treatment and control groups were fed with MBP-
fMSTNpro45-100mFc (10 µg/g pup) and PBS, respectively, twice one day apart. Using a blunt 
pipet tip, the solution containing the recombinant proteins or PBS were delivered into the middle 
of the mouth for pups to swallow the solution. The pups were weaned at 4 weeks, and their body 
weight were measured weekly for 7 weeks after weaning. At 11 weeks after weaning, animals 
were sacrificed by CO2 asphyxiation, and gastrocnemius complex (gastrocnemius, plantaris and 
soleus) muscle and organ (heart, liver, spleen, kidney) samples were collected and weighed. 
Intraperitoneal injection of MBP-fMSTNpro45-100mFc in neonatal mice 
Eight female (7-month-old) and two male (7-month-old) B6SJLF1/J mice were housed in 
Small Animal Facility at 12 hr/12 hr light-dark cycles. Mice were fed with commercial rodent 
diet with clean water ad libitum. Four female mice were mated to each male, and the female 
mice were randomly divided into two groups: control and treatment. Newborn pups in the 
treatment and control groups were intraperitoneally injected MBP-fMSTNpro45-100mFc (10 
µg/g pup) and PBS, respectively, on the first and second day after birth. Mice body weight were 
monitored weekly for 6 weeks after weaning. At 10 weeks after weaning, mice were sacrificed 
by CO2 asphyxiation and gastrocnemius complex (gastrocnemius, plantaris and soleus) muscle 
and organ (heart, liver, spleen, kidney) samples were collected and weighed. 
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2.4. Results  
2.4.1. Optimization of inducible expression of MBP-fMSTNpro45-100mFc 
Figure 1 shows the result of SDS-PAGE analysis of expression of MBP-fMSTNpro45-
100mFc under different induction time. The construct was designed to express a 77.5 kDa 
protein consisting of 42.5 kDa MBP, 10 kDa fMSTNpro45-100 and 25 kDa mouse IgG Fc 
domain. SDS-PAGE analysis of cell lysates showed that most of the induced recombinant 
proteins were in the supernatant fraction, indicating that the MBP-fMSTNpro45-100mFc was 
mainly expressed in soluble forms. From the result, six hours of induction contained the least 
amount of off-target proteins compared with the other induction period, indicating that 4 h 
expression is the optimum induction time. The soluble fraction contained about 89 mg/L proteins 
with MBP-fMSTNpro45-100mFc being the highest proportion (Table 2). 
2.4.2. Amylose resin affinity chromatography purification of MBP-fMSTNpro45-100mFc 
proteins 
The soluble fraction was applied to amylose resin and eluted by the column buffer 
containing 10 mM maltose after washing with column buffer. When analyzed by SDS-PAGE, the 
elution fractions contained mostly the recombinant MBP-fMSTNpro45-100mFc proteins at 77.5 
kDa with many other proteins found in the soluble fraction being removed (Fig.2). About 23.2 
mg/L of MBP-fMSTNpro45-100mFc protein were purified by affinity chromatography, 
contributing to around 26.1% recovery from the total soluble proteins (Table 2). 
2.4.3. Protein A affinity chromatography purification of MBP-fMSTNpro45-100mFc 
proteins 
After amylose chromatography, to further purify the MBP-fMSTNpro45-100mFc 
proteins, eluted fractions of MBP-fMSTNpro45-100mFc with high OD (OD>1.0) and eluted 
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fractions with low OD (0.1-1.0) were pooled separately and subjected to Protein A column 
separately. As shown in Fig. 3, a majority of proteins around and below 50 kDa was removed 
from the affinity-purified elutions. About 7.52 mg/L of MBP-fMSTNpro45-100mFc protein 
(8.4% of the total proteins) was recovered by protein A affinity chromatography (Table 2). 
2.4.4. Bioactivity test for the MBP-fMSTNpro45-100mFc proteins using pGL3-(CAGA)12-
Luciferase reporter assay 
The purified MBP-fMSTNpro45-100mFc protein was examined for its capacity to 
suppress MSTN activity using the pGL3-(CAGA)12-Luciferase reporter assay system in HEK293 
cells. The commercially available MSTNpro was used as a positive control. Both commercial 
MSTN propeptide and MBP-fMSTNpro45-100mFc demonstrated dose-dependent inhibition of 
MSTN (Fig. 4). The IC50 value of MBP-fMSTNpro45-100mFc was not significantly different 
from that of commercial MSTNpro (Fig. 4), indicating that the MSTN-inhibitory potency of 
MBP-fMSTNpro45-100mFc is as good as the commercial MSTNpro produced in a eukaryotic 
expression system.  
2.4.5. The effect of MBP-fMSTNpro45-100mFc protein on body weight growth of neonatal 
mice 
Figure 5 and 6 show the body weight growth after the neonatal administration of MBP-
fMSTNpro45-100mFc. The body weight growth of mice with either neonatal oral administration 
or intraperitoneal injection of MBP-fMSTNPro45-100mFc did not differ from that of control 
mice, indicating that neonatal administration of MBP-fMSTNPro45-100mFc did not influence 
body weight growth in mice.  
2.4.6. The effect of MBP-fMSTNpro45-100mFc protein on skeletal muscle and organ 
weights of neonatal mice 
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6-7 weeks after weaning, mice were sacrificed and dissected. Gastrocnemius complex 
which includes gastrocnemius, soleus and plantaris muscle and organs (heart, liver, spleen, 
kidney and epididymal fat) were separated and weighed. Table 2 and 3 show that neither 
neonatal oral feeding nor neonatal intraperitoneal injection of MBP-fMSTNpro45-100mFc 
influenced the weights of skeletal muscle and organs. 
2.5. Discussion 
Expression of bioactive proteins of interest with high a quantity is very important in 
biological research, in which recombinant protein is designed to be used in in vivo animal 
studies. Mostly, E. coli is an effective host for fast cloning of target genes and expression of 
recombinant proteins because of its simple handling, low cost and high yields of recombinant 
proteins. Thus, there were some efforts to produce MSTN inhibitors, such as MSTNpro, in E. 
coli. The first trial of fish MSTNpro production in E. coli resulted in insoluble expression of 
recombinant protein (Rebhan and Funkenstein, 2008), requiring a folding process with an 
extremely low yield of bioactive protein. However, when MBP was used as a fusion partner, 
bioactive fish MSTNpro was expressed in a soluble form in E. coli (Lee et al., 2010). 
Subsequently, bioactive porcine MSTNpro was also expressed in a soluble form (Haq et al., 
2013). Furthermore, various truncated forms of fish and porcine MSTNpro with comparable 
MSTN-inhibitory capacity were also expressed in E. coli (Lee et al., 2016). In this study, we 
used a mouse IgG Fc domain fused, truncated form of MSTNpro (MBP-fMSTNpro45-100mFc). 
The Fc fusion to recombinant protein is generally known to prolong the half-life of recombinant 
proteins. In a study, researchers constructed recombinant Factor VIII-Fc fusion protein to 
prolong the half-life of Factor VIII for enhanced treatment of Hemophilia A (Dumont et al., 
2012). The recombinant Factor VIII-Fc fusion protein had an approximately 2-fold longer half-
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life than Factor VIII without Fc in Hemophilia A mice and dogs. The extension of half-life 
requires the interaction of Fc with the neonatal Fc receptor (FcRn). In FcRn knockout mice, the 
extension of rFVIIIFc half-life is abrogated, and is restored in human FcRn transgenic mice 
(Dumont et al., 2012). IgG Fc domain could also facilitate purification of its fused protein by 
protein A column. After large amounts expression, the MBP-fMSTNpro45-100mFc proteins 
were purified by amylose resin and protein A column. Luciferase assay was also conducted to 
test the bioactivity of recombinant MSTNpro. The result showed that the biological activity of 
MBP-fMSTNpro45-100mFc is similar to commercial MSTNpro, efficiently suppressing MSTN 
activity.  
After successfully expressing bioactive recombinant MSTNpro, we examined whether 
the administration of the recombinant MSTNpro in neonatal mice would affect their postnatal 
body weight and muscle growth. Previous studies indicated that muscle hyperplasia continue 
during the early neonatal period in some altricial species like rabbit and rat (Nougues et al., 
1972; Oron, 1990), suggesting the potential of enhancing muscle hyperplasia in some species via 
MSTN suppression. Thus, it was postulated that the MSTNpro administration in neonatal mice 
would potentially increase muscle fiber number and subsequent increase in body weight and 
muscle growth. The newborn pups were orally fed and intraperitoneally injected with 
recombinant MSTNpro at the first and second day after birth. After 10 and 11 weeks, the skeletal 
muscle, organs and body weight data were collected. The results showed that the mass of 
gastrocnemius muscle and body weight were not significantly increased after the neonatal 
administration of recombinant MSTNpro, implying that the administration of MBP-
fMSTNpro45-100mFc in the early neonatal period did not enhance muscle hyperplasia in mice. 
However, this study did not examine either the transfer of recombinant MSTNpro into 
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circulation or the muscle fiber number after the administration. Furthermore, dose-response was 
not examined. Further studies are needed to validate the potential of neonatal suppression of 
MSTN as a strategy to improve skeletal muscle growth of animals. 
2.6. Conclusion 
A bioactive, mouse Fc domain fused, truncated form of MSTNpro (MBP-fMSTNpro45-
100mFc) was successfully produced in E. coli in order to examine the effect of neonatal 
administration of the protein on postnatal body weight and muscle growth. The neonatal 
administration of recombinant MSTNpro did not increase the mass of gastrocnemius muscle and 
body weight, implying that the administration of MBP-fMSTNpro45-100mFc in the early 
neonatal period did not enhance muscle hyperplasia in mice. But concluding muscle hyperplasia 
could not be induced by the neonatal administration of recombinant MSTNpro seems still too 
early. The current study did not examine if the recombinant MSTNpro is transferred into animal 
circulation by our administration, nor the dose-response of recombinant MSTNpro. Therefore, 
further studies are needed to confirm if the neonatal administration of MSTNpro can be a 
potential strategy to improve skeletal muscle growth of animals. 
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Table 1. Primer sequences used in Gibson assembly cloning 
Underlined, lower case letters indicate overlapping sequences. 
Red color is linker (G4S, ggcggcggcggctct). 
Bold is stop codon. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer 
  
Sequence 
 
Pro45-100-F  gggatcgagggaaggTGCGACTAAACGCGATCATAT  
Pro45-100-R agagccgccgccgccCAGCACGTCGTACTGGTCGAG 
IgG Fc-F gacgtgctgggcggcggcggctctGGCTGTAAACCGT 
IgG Fc-R catggacatatgtgaaatTCATTTGCCCGGCGAGTG 
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Table 2.  Yield of MBP-fMSTNpro45-100mFc recovered from each purification step 
The protein concentration was measured by the Lowry protein assay using BSA as a standard. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Recovery of protein per Liter 
E. coli culture (mg/L) 
Yield (%) 
Total soluble protein 89 100.0 
Amylose affinity-purified 
protein 
23.2 26.1 
Protein A affinity-purified 
protein 
7.52 8.4 
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Table 3. Muscle and organ weights in oral feeding experiments at 11 weeks 
Data are least square means (SEM). *: P<0.05, **: P<0.01, ***: P<0.001 
Gas complex, gastrocnemius complex which includes gastrocnemius, soleus and plantaris. 
The muscle or organ % is relative to body weight. 
Wks: Weeks 
 
 Control Treatment TRT SEX TRT x SEX 
Female  
(n=17) 
Male  
(n=12) 
Female  
(n=12) 
Male  
(n=9) 
   
Gas complex, g 0.211 
(0.0049) 
0.293 
(0.0081) 
0.221 
(0.0068) 
0.295 
(0.0149) 
NS *** NS 
Gas complex % 1.013 
(0.0200) 
1.142 
(0.0283) 
1.057 
(0.0227) 
1.114 
(0.0656) 
NS ** NS 
Liver, g 1.103 
(0.0259) 
1.338 
(0.0503) 
1.153 
(0.0305) 
1.194 
(0.0593) 
NS ** * 
Liver % 5.306 
(0.0885) 
5.212 
(0.1407) 
5.520 
(0.0812) 
4.840 
(0.2360) 
NS ** * 
Heart, g 0.110 
(0.0025) 
0.121 
(0.0026) 
0.112 
(0.0016) 
0.121 
(0.0028) 
NS *** NS 
Heart % 0.527 
(0.0113) 
0.474 
(0.0118) 
0.539 
(0.0091) 
0.492 
(0.0164) 
NS *** NS 
Kidney, g 0.331 
(0.0065) 
0.441 
(0.0109) 
0.363 
(0.0088) 
0.435 
(0.0246) 
NS *** NS 
Kidney % 1.591 
(0.0246) 
1.720 
(0.0344) 
1.737 
(0.0261) 
1.756 
(0.0874) 
* NS NS 
Spleen, g 0.089 
(0.0044) 
0.090 
(0.0045) 
0.099 
(0.0049) 
0.089 
(0.0047) 
NS NS NS 
Spleen % 0.421 
(0.0210) 
0.351 
(0.0155) 
0.477 
(0.0261) 
0.359 
(0.0151) 
NS *** NS 
 Male (n=12) Male (n=9) TRT 
Epidydimal fat, 
g 
0.305 
(0.0273) 
0.277 
(0.0254) 
NS 
Epidydimal 
fat % 
1.128 
(0.1123) 
1.111 
(0.0880) 
NS 
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Table 4. Muscle and organ weights of mice in intraperitoneal injection experiments at 10  
weeks 
Data are least square means (SEM). *: P<0.05, **: P<0.01, ***: P<0.001 
Gas complex, gastrocnemius complex which includes gastrocnemius, soleus and plantaris. 
The muscle or organ % is relative to body weight. 
 Control Treatment TR
T 
SE
X 
TRT x 
SEX 
Female  
(n=6) 
Male  
(n=9) 
Female  
(n=17) 
Male 
 (n=14) 
   
Gas complex, g 0.221 
(0.0085) 
0.320 
(0.0112) 
0.217 
(0.0053) 
0.321 
(0.0092) 
NS *** NS 
Gas complex % 1.057 
(0.0269) 
1.245 
(0.0219) 
1.092 
(0.0139) 
1.281 
(0.0285) 
NS *** NS 
Liver, g 1.021 
(0.0832) 
1.285 
(0.0270) 
1.013 
(0.0309) 
1.297 
(0.0415) 
NS *** NS 
Liver % 4.869 
(0.3488) 
5.024 
(0.1011) 
5.116 
(0.1263) 
5.187 
(0.1358) 
NS NS NS 
Heart, g 0.110 
(0.0048) 
0.118 
(0.0042) 
0.106 
(0.0018) 
0.121 
(0.0027) 
NS *** NS 
Heart % 0.532 
(0.0289) 
0.456 
(0.0163) 
0.535 
(0.0106) 
0.484 
(0.0070) 
NS *** NS 
Kidney, g 0.405 
(0.0578) 
0.424 
(0.0150) 
0.310 
(0.0060) 
0.400 
(0.0164) 
** * NS 
Kidney % 1.956 
(0.3227) 
1.653 
(0.0414) 
1.570 
(0.0268) 
1.595 
(0.0446) 
* NS NS 
Spleen, g 0.107 
(0.0131) 
0.086 
(0.0065) 
0.087 
(0.0034) 
0.111 
(0.0149) 
NS NS NS 
Spleen % 0.519 
(0.0725) 
0.334 
(0.0244) 
0.439 
(0.0184) 
0.452 
(0.0690) 
NS NS NS 
 Male (n=9) Male (n=14) TRT 
Epidydimal fat, 
g 
0.284 
(0.0432) 
0.194 
(0.0334) 
NS 
Epidydimal 
fat % 
1.108 
(0.1724) 
0.764 
(0.1262) 
NS 
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Wks: Weeks 
 
 
Figure 1. SDS-PAGE analysis of recombinant MBP-fMSTNpro45-100mFc expression during 
different induction period. To determine the optimum induction time for MBP-fMSTNpro45-
100mFc expression in E. coli, culture samples were collected at 4, 6, 8, 10, and 12 hr after induction 
by IPTG (0.5 mM) at room temperature. Cells were collected by centrifugation, then cell pellets 
were lysed, followed by SDS-PAGE analysis of total lysate, soluble and insoluble fractions. Arrow 
indicates MBP-fMSTNpro45-100mFc. M, protein marker; L, lysate; S, supernatant; P, pellet. 
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Figure 2. SDS-PAGE analysis of MBP-fMSTNpro45-100mFc purified by amylose affinity- 
chromatography. After 4h inducible expression at room temperature, cell pellets were collected, 
mixed with amylose affinity binding buffer, and lysed by sonication. The soluble fraction of lysate 
was collected by centrifugation and was subjected to amylose resin affinity chromatography. 
Elution fractions showing high OD280 were subjected to SDS-PAGE analysis.  Arrow indicates 
amylose resin affinity-purified MBP-fMSTNpro45-100mFc. M, protein marker; L, lysate; S, 
supernatant; P, pellet; PT, pass-through. 
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Figure 3. SDS-PAGE analysis of MBP-fMSTNpro45-100mFc purified by protein A affinity-
chromatography. After amylose affinity chromatography, eluted fractions containing MBP-
fMSTNpro45-100mFc with high OD (OD>1.0) and eluted fractions with low OD (0.1-1.0) were 
pooled separately. The high OD collection and low OD collection were then subjected to protein 
A affinity chromatography separately. Arrow indicates protein A affinity-purified MBP-
fMSTNpro45-100mFc. M, protein marker; P1, pooled low OD (0.1-1.0) fractions of amylose-
affinity purification; P2: pooled high OD (OD>1.0) fractions of amylose-affinity purification; PT, 
pass-through. 
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Figure 4. Inhibition of Myostatin activity by MBP-fMSTNpro45-100mFc. HEK293 cell stably 
expressing (CAGA)12-luciferase gene construct were used. Gradient concentrations of MBP-
fMSTNpro45-100mFc in combination with 1 nM Myostatin were added to HEK293 cells, then 
incubated for 24 h. After that, medium was replaced by luminescence substrate and luminescence 
was measured. The error bars represent SEM (n = 3). NS: The means of IC50 are not significantly 
different. 
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Figure 5. The effect of neonatal oral administration of MBP-fMSTNPro45-100mFc on post-
weaning body weight growth. Neonatal mice in treatment groups were treated by oral feeding of 
10 ug/pup MBP-fMSTNPro45-100-mFc and neonatal mice in control groups were treated by oral 
feeding of PBS. After 4 weeks, mice were weaned, and body weights were monitored weekly for 
7 weeks. 
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Figure 6. The effect of neonatal intraperitoneal administration of MBP-fMSTNPro45-100mFc on 
Post-weaning body weight growth in mice. Neonatal mice in treatment groups were treated by 
intraperitoneal injection of 10 ug/pup MBP-fMSTNPro45-100mFc and neonatal mice in control 
groups were treated by intraperitoneal injection of PBS. After 4 weeks, mice were weaned, and 
body weights were monitored weekly for 6 weeks. 
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Appendix 1. Body weight growth of mice in experiment 1 (Oral feeding) 
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Trt, treatment 
Appendix 2. Body weight growth of mice in experiment 2 (Intraperitoneal injection) 
Dam Sire Mouse # Sex Trt 4 wk 5 wk 6 wk 7 wk 8 wk 9 wk 10 wk 11 wk Total gain
8 75 76 F C 14.0 17.8 18.0 19.2 19.4 20.1 20.1 20.3 6.3
8 75 77 F C 13.5 17.8 18.7 19.0 20.1 20.5 20.5 20.7 7.2
8 75 78 F C 15.1 17.8 18.3 19.5 20.1 20.6 20.2 20.5 5.4
8 75 79 F C 14.1 16.4 16.2 17.5 18.8 19.3 20.3 20.2 6.1
8 75 80 F C 13.8 17.4 17.4 18.3 18.9 19.0 19.7 19.6 5.8
8 75 81 F C 12.3 15.9 16.3 17.3 17.9 18.6 19.6 20.4 8.1
8 75 82 F C 14.0 18.1 18.6 19.3 20.5 20.6 21.3 21.2 7.2
21 23 16 F C 13.9 17.5 17.3 17.4 17.7 18.7 18.8 20.0 6.1
21 23 17 F C 13.4 16.5 17.1 17.9 18.5 19.5 19.7 20.3 6.9
21 23 47 F C 11.1 14.8 17.4 17.8 18.3 18.3 18.9 20.1 9.0
21 23 48 F C 12.9 16.4 18.1 19.1 19.5 20.2 19.8 20.0 7.1
24 23 179 F C 16.0 19.6 19.2 19.0 19.7 20.1 21.0 22.5 6.5
24 23 181 F C 14.0 18.3 19.1 19.2 20.5 20.7 20.9 21.4 7.4
24 23 182 F C 16.4 20.3 21.2 20.4 21.7 22.0 22.2 23.2 6.8
24 23 183 F C 12.6 16.1 17.8 17.4 18.2 18.5 19.4 19.2 6.6
24 23 184 F C 17.0 20.2 19.8 20.1 21.4 21.6 22.9 22.0 5.0
24 23 185 F C 16.3 21.0 20.5 19.7 20.5 20.9 21.8 21.6 5.3
8 75 83 M C 13.5 18.9 20.3 22.3 23.6 24.6 25.9 25.6 12.1
8 75 84 M C 14.5 19.6 21.0 22.1 23.0 23.7 24.0 24.2 9.7
8 75 85 M C 12.9 19.9 21.5 22.6 23.8 24.7 25.0 24.6 11.7
8 75 86 M C 14.1 21.0 21.9 22.8 23.8 24.1 25.0 25.2 11.1
21 23 11 M C 12.5 20.2 21.0 21.8 22.9 23.8 25.3 25.8 13.3
21 23 12 M C 12.2 19.3 21.3 22.5 24.1 25.4 26.5 27.4 15.2
21 23 13 M C 12.8 19.0 20.0 22.6 24.5 25.6 27.1 26.9 14.1
21 23 14 M C 13.2 19.8 21.0 21.9 22.2 23.6 24.6 25.4 12.2
21 23 15 M C 15.0 20.7 21.9 24.1 24.6 25.6 27.3 26.5 11.5
21 23 18 M C 13.2 19.8 20.9 21.6 21.1 22.1 22.4 22.4 9.2
24 23 72 M C 16.3 23.1 23.3 25.4 26.0 25.9 26.8 27.5 11.2
24 23 178 M C 15.2 22.1 23.1 23.1 23.4 23.7 25.4 25.9 10.7
10 23 97 F T 13.9 17.9 17.4 19.1 18.8 19.0 19.3 19.7 5.8
10 23 59 F T 15.2 17.6 18.6 19.4 19.5 20.1 23.2 21.0 5.8
10 23 61 F T 14.7 17.5 17.2 17.9 17.8 18.6 19.0 19.1 4.4
20 23 87 F T 14.1 17.7 17.1 18.5 18.6 20.2 20.7 21.0 6.9
20 23 88 F T 14.8 20.2 20.2 21.2 21.1 21.2 20.3 22.5 7.7
22 75 49 F T 14.1 17.6 18.3 19.4 19.7 20.2 20.8 21.2 7.1
22 75 50 F T 16.9 21.7 20.8 19.5 18.8 21.2 20.5 20.5 3.6
22 75 62 F T 14.5 18.1 18.1 21.0
22 75 65 F T 13.0 16.2 16.2 17.5 18.0 21.2 20.8 21.4 8.4
22 75 66 F T 14.2 16.7 18.4 19.8 21.3 20.2 22.1 21.4 7.2
22 75 67 F T 13.9 17.6 17.1 17.8 18.0 20.6 20.1 20.0 6.1
22 75 68 F T 15.1 16.9 18.3 18.4 18.0 19.6 22.0 22.5 7.4
22 75 71 F T 12.8 16.1 16.9 17.2 18.2 20.2 19.6 20.0 7.2
9 75 152 F T 9.4 14.5 18.6 19.3 18.9 19.6 20.1 21.5 12.1
9 75 153 F T 9.4 15.1 17.9 17.9 18.0 18.8 20.1 20.0 10.6
9 75 155 F T 8.8 12.9 15.2 15.1 14.9 14.6 14.5 15.3 6.5
9 75 158 F T 9.4 14.1 17.4 17.6 17.9 18.3 18.4 18.8 9.4
9 75 159 F T 11.4 15.8 17.6 17.6 17.6 17.8 19.5 19.6 8.2
9 75 160 F T 8.5 13.3 15.2 15.6 17.3 18.1 18.2 18.8 10.3
9 75 162 F T 9.1 14.6 17.8 18.2 18.3 19.2 19.1 21.1 12.0
22 75 63 M T 14.5 18.0 18.5 21.2 21.4 21.7 22.4 23.0 8.5
10 23 89 M T 18.2 22.9 21.8 22.6 23.6 24.1 24.4 24.7 6.5
10 23 90 M T 18.1 22.9 23.9 24.3 24.4 25.7 26.7 27.1 9.0
10 23 91 M T 17.2 20.5 20.5 21.0 21.8 23.0 22.6 23.6 6.4
10 23 93 M T 17.5 22.7 23.6 25.1 25.9 26.4 Miss 26.2 8.7
10 23 96 M T 16.9 22.7 23.5 24.2 25.1 26.5 28.3 27.3 10.4
10 23 98 M T 17.9 22.7 23.3 24.2 25.6 25.4 27.0 25.1 7.2
20 23 92 M T 13.9 18.1 20.4 22.9 23.5 23.7 24.9 24.6 10.7
20 23 94 M T 13.2 18.9 18.7 18.4 19.9 19.9 21.2 21.2 8.0
9 75 151 M T 10.7 16.8 20.6 21.0 21.6 22.4 23.3 25.4 14.7
9 75 154 M T 10.2 16.5 20.6 22.6 22.4 22.8 23.0 23.3 13.1
9 75 156 M T 11.1 18.5 21.9 23.1 23.3 23.2 24.2 25.0 13.9
9 75 157 M T 8.0 14.3 19.2 20.5 21.1 22.1 23.5 24.8 16.8
9 75 161 M T 9.6 17.4 19.6 21.7 22.5 23.2 23.7 24.8 15.2
Sacrificed due to unexpected pregnancy
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Trt, treatment 
Appendix 3. Muscle and organ weight of mice upon sacrifice in experiment 1 
Dam Sire Mouse # Sex Trt 4 wk 5 wk 6 wk 7 wk 8 wk 9 wk 10 wk Total gain
22 23 116 F C 16.7 18.8 19.4 20.5 21.4 21.6 23.5 6.8
22 23 119 F C 17.6 18.4 19.3 19.9 20.7 22.0 21.6 4.0
22 23 121 F C 17.4 18.1 18.6 19.3 20.5 21.3 19.8 2.4
21 75 101 F C 16.4 17.8 18.6 19.6 21.0 22.2 19.3 2.9
198 75 488 F C 16.3 16.7 17.2 17.8 18.2 18.3 19.7 3.4
198 75 490 F C 17.0 19.3 19.6 21.6 21.9 21.3 21.8 4.8
22 23 117 M C 19.0 22.1 23.8 24.3 24.9 25.3 24.6 5.6
22 23 118 M C 16.5 19.3 20.8 21.4 22.6 23.4 23.7 7.2
22 23 120 M C 18.9 21.0 22.7 23.7 24.5 25.3 25.0 6.1
198 75 487 M C 20.3 21.1 21.4 23.5 24.2 24.9 25.4 5.1
198 75 489 M C 19.2 20.2 21.1 22.9 23.7 24.5 24.5 5.3
198 75 491 M C 20.1 22.7 24.0 25.8 26.6 26.8 27.4 7.3
198 75 492 M C 19.5 20.2 21.4 22.6 22.9 23.7 25.0 5.5
21 75 494 M C 20.4 22.6 23.5 25.1 25.6 26.6 27.9 7.5
21 75 493 M C 20.3 23.3 26.4 24.8 25.9 26.5 26.9 6.6
20 75 172 F T 14.0 16.9 18.3 20.3 21.4 20.6 21.5 7.5
20 75 169 F T 15.7 17.9 18.1 18.7 19.6 20.0 20.7 5.0
8 23 166 F T 15.3 16.6 16.8 18.3 19.3 19.8 19.4 4.1
8 23 165 F T 17.4 18.9 19.0 19.8 21.5 21.6 21.3 3.9
8 23 499 F T 16.6 18.0 18.7 18.9 20.6 21.3 21.2 4.6
8 23 483 F T 17.2 17.8 18.0 18.7 19.5 19.7 20.7 3.5
8 23 495 F T 17.3 18.6 18.9 19.6 20.4 20.8 20.9 3.6
8 23 486 F T 14.8 15.8 15.0 16.8 17.6 17.8 19.0 4.2
9 23 103 F T 12.1 15.5 21.6 18.0 18.6 18.6 18.6 6.5
9 23 104 F T 13.9 16.8 21.6 19.0 19.5 21.3 19.3 5.4
9 23 105 F T 15.5 16.3 21.8 17.6 18.8 19.5 19.1 3.6
9 23 107 F T 13.3 16.0 21.8 17.6 18.9 19.2 19.1 5.8
9 23 108 F T 16.5 18.0 23.3 19.6 20.0 20.8 20.8 4.3
9 23 110 F T 12.6 14.9 20.3 16.0 16.8 16.7 16.7 4.1
9 23 112 F T 15.7 18.6 23.6 19.2 19.9 20.7 20.0 4.3
9 23 113 F T 13.2 16.8 22.1 18.4 19.0 19.3 19.8 6.6
9 23 114 F T 14.0 16.4 22.1 16.8 17.0 16.8 18.4 4.4
20 75 174 M T 14.0 18.7 17.7 19.8 20.7 21.1 22.3 8.3
20 75 173 M T 15.7 19.5 21.0 22.9 23.5 24.2 24.5 8.8
20 75 164 M T 14.7 18.1 19.6 20.8 21.6 22.7 23.0 8.3
20 75 171 M T 16.0 20.1 21.6 22.4 22.9 24.4 25.4 9.4
20 75 170 M T 16.3 20.4 21.7 23.7 24.2 26.9 26.4 10.1
20 75 168 M T 16.1 21.3 22.9 24.3 25.0 26.5 26.4 10.3
20 75 167 M T 15.4 20.9 22.2 23.9 24.5 25.1 25.2 9.8
8 23 498 M T 18.2 20.6 21.3 23.1 23.9 25.0 25.6 7.4
8 23 497 M T 18.8 22.8 24.2 26.6 26.6 27.1 26.8 8.0
8 23 496 M T 18.3 22.9 24.4 25.6 26.6 26.7 27.7 9.4
8 23 484 M T 17.0 20.0 21.5 23.0 24.2 24.7 26.2 9.2
9 23 102 M T 12.8 17.4 22.2 19.3 20.3 22.7 22.5 9.7
9 23 106 M T 14.5 18.8 23.0 20.3 21.2
9 23 109 M T 15.8 21.4 26.6 23.5 24.6 25.7 25.2 9.4
9 23 111 M T 14.9 20.4 23.0 22.3 23.9
9 23 115 M T 11.5 18.3 24.4 21.9 22.6 22.6 22.9 11.4
Sacrificed due to illness
Sacrificed due to illness
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Trt, treatment 
Gas, gastrocnemius complex 
Appendix 4. Muscle and organ weights of mice upon sacrifice in experiment 2 
Dam Sire Mouse # Sex Trt Gas % Gas Liver % Liver Heart % Heart Kidney % Kidney Spleen % Spleen Epidydimal fat % Epidydimal fat
8 75 83 M C 0.293 1.145 1.097 4.287 0.103 0.402 0.420 1.639 0.077 0.302 0.492 1.922
8 75 84 M C 0.314 1.297 1.159 4.789 0.135 0.558 0.372 1.539 0.074 0.304 0.202 0.836
8 75 85 M C 0.310 1.259 1.222 4.965 0.119 0.482 0.377 1.532 0.086 0.351 0.312 1.268
8 75 86 M C 0.291 1.155 1.309 5.195 0.127 0.502 0.466 1.849 0.119 0.472 0.118 0.466
21 23 11 M C 0.297 1.150 1.305 5.058 0.124 0.479 0.483 1.874 0.095 0.367 0.293 1.136
21 23 12 M C 0.296 1.080 1.576 5.750 0.124 0.451 0.469 1.713 0.114 0.415 0.260 0.948
21 23 13 M C 0.282 1.047 1.416 5.265 0.116 0.430 0.460 1.709 0.086 0.320 0.390 1.449
21 23 14 M C 0.285 1.122 1.248 4.913 0.117 0.462 0.423 1.667 0.086 0.337 0.169 0.666
21 23 15 M C 0.340 1.284 1.358 5.123 0.120 0.453 0.473 1.786 0.093 0.350 0.248 0.935
21 23 18 M C 0.218 0.974 1.189 5.309 0.112 0.500 0.420 1.875 0.066 0.294 0.282 1.257
24 23 72 M C 0.293 1.064 1.656 6.023 0.127 0.460 0.457 1.663 0.084 0.307 0.343 1.245
24 23 178 M C 0.293 1.132 1.521 5.873 0.132 0.510 0.466 1.801 0.101 0.392 0.363 1.402
22 75 63 M T 0.252 1.093 1.222 5.313 0.124 0.538 0.425 1.849 0.069 0.300 0.162 0.703
10 23 89 M T 0.291 1.179 1.025 4.149 0.130 0.524 0.365 1.477 0.085 0.345 0.249 1.006
10 23 90 M T 0.336 1.239 0.952 3.514 0.124 0.459 0.387 1.430 0.083 0.306 0.348 1.285
10 23 91 M T 0.262 1.111 1.070 4.534 0.108 0.458 0.361 1.530 0.080 0.340 0.311 1.319
10 23 93 M T 0.366 1.396 1.218 4.648 0.108 0.413 0.451 1.721 0.105 0.401 0.414 1.580
10 23 96 M T 0.317 1.161 1.397 5.118 0.122 0.445 0.545 1.997 0.110 0.401 0.253 0.927
10 23 98 M T 0.292 1.164 1.451 5.782 0.128 0.508 0.453 1.803 0.083 0.331 0.308 1.226
20 23 92 M T 0.247 1.004 1.351 5.493 0.131 0.531 0.553 2.249 0.105 0.428 0.231 0.937
20 23 94 M T 0.143 0.675 1.062 5.008 0.117 0.552 0.371 1.749 0.081 0.382 0.215 1.015
10 23 97 F T 0.191 0.969 1.082 5.493 0.114 0.578 0.348 1.768 0.116 0.589
10 23 59 F T 0.232 1.104 1.249 5.949 0.113 0.537 0.374 1.781 0.102 0.486
10 23 61 F T 0.195 1.018 0.980 5.133 0.106 0.553 0.323 1.693 0.111 0.581
20 23 87 F T 0.213 1.012 1.099 5.235 0.125 0.596 0.325 1.549 0.109 0.520
20 23 88 F T 0.266 1.180 1.303 5.792 0.113 0.502 0.420 1.867 0.086 0.383
22 75 49 F T 0.210 0.989 1.110 5.237 0.109 0.514 0.357 1.682 0.108 0.510
22 75 50 F T 0.228 1.112 1.127 5.495 0.109 0.534 0.343 1.675 0.099 0.483
22 75 65 F T 0.210 0.981 1.253 5.856 0.107 0.502 0.387 1.809 0.105 0.491
22 75 66 F T 0.206 0.963 1.151 5.379 0.121 0.564 0.353 1.651 0.100 0.469
22 75 67 F T 0.211 1.055 1.082 5.408 0.108 0.538 0.363 1.814 0.052 0.259
22 75 68 F T 0.262 1.162 1.324 5.886 0.112 0.499 0.411 1.825 0.094 0.418
22 75 71 F T 0.227 1.134 1.075 5.375 0.111 0.556 0.346 1.730 0.107 0.536
8 75 76 F C 0.230 1.135 1.006 4.955 0.105 0.519 0.315 1.553 0.098 0.481
8 75 77 F C 0.215 1.037 0.972 4.693 0.112 0.543 0.333 1.607 0.093 0.449
8 75 78 F C 0.215 1.049 0.978 4.772 0.121 0.591 0.307 1.498 0.078 0.380
8 75 79 F C 0.186 0.918 1.058 5.238 0.103 0.510 0.305 1.507 0.115 0.569
8 75 80 F C 0.223 1.139 0.938 4.784 0.127 0.647 0.313 1.595 0.076 0.389
8 75 81 F C 0.172 0.841 1.059 5.190 0.095 0.466 0.292 1.432 0.098 0.479
8 75 82 F C 0.225 1.062 1.177 5.554 0.101 0.477 0.329 1.550 0.074 0.350
21 23 16 F C 0.188 0.940 1.046 5.228 0.106 0.530 0.308 1.540 0.085 0.425
21 23 17 F C 0.213 1.047 1.028 5.062 0.109 0.539 0.315 1.553 0.077 0.379
21 23 47 F C 0.183 0.912 1.094 5.444 0.103 0.514 0.328 1.630 0.058 0.289
21 23 48 F C 0.199 0.996 1.123 5.615 0.100 0.501 0.361 1.807 0.059 0.297
24 23 179 F C 0.235 1.042 1.310 5.822 0.114 0.506 0.345 1.531 0.113 0.504
24 23 181 F C 0.232 1.082 1.205 5.630 0.110 0.512 0.314 1.469 0.106 0.493
24 23 182 F C 0.214 0.924 1.259 5.428 0.131 0.563 0.391 1.685 0.105 0.451
24 23 183 F C 0.189 0.983 1.136 5.915 0.099 0.517 0.336 1.752 0.106 0.552
24 23 184 F C 0.234 1.063 1.219 5.541 0.102 0.461 0.376 1.710 0.064 0.291
24 23 185 F C 0.227 1.050 1.151 5.330 0.123 0.569 0.352 1.628 0.084 0.388
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Trt, treatment 
Gas, gastrocnemius complex 
References   
Dam Sire Mouse # Sex Trt Gas % Gas Liver % Liver Heart % Heart Kidney % Kidney Spleen % Spleen Epidydimal fat % Epidydimal fat
22 23 117 M C 0.298 1.213 1.219 4.954 0.127 0.515 0.400 1.628 0.067 0.272 0.186 0.757
22 23 118 M C 0.264 1.114 1.191 5.023 0.105 0.442 0.352 1.485 0.061 0.259 0.474 2.002
22 23 120 M C 0.317 1.268 1.331 5.322 0.101 0.403 0.393 1.572 0.107 0.429 0.132 0.528
198 75 487 M C 0.314 1.236 1.252 4.929 0.111 0.438 0.466 1.833 0.093 0.367 0.438 1.724
198 75 489 M C 0.306 1.248 1.364 5.569 0.137 0.558 0.442 1.803 0.071 0.291 0.130 0.532
198 75 491 M C 0.360 1.314 1.424 5.196 0.125 0.458 0.474 1.731 0.110 0.403 0.337 1.230
198 75 492 M C 0.302 1.208 1.224 4.897 0.107 0.429 0.373 1.491 0.107 0.429 0.220 0.880
21 75 494 M C 0.374 1.339 1.337 4.793 0.120 0.431 0.462 1.656 0.071 0.254 0.386 1.382
21 75 493 M C 0.341 1.267 1.220 4.536 0.117 0.433 0.452 1.679 0.082 0.303 0.253 0.941
20 75 174 M T 0.234 1.048 1.432 6.420 0.116 0.522 0.343 1.539 0.292 1.309 0.000 0.000
20 75 173 M T 0.292 1.193 1.241 5.066 0.128 0.522 0.325 1.327 0.114 0.467 0.247 1.008
20 75 164 M T 0.326 1.416 1.086 4.720 0.114 0.497 0.369 1.602 0.086 0.374 0.177 0.770
20 75 171 M T 0.340 1.339 1.316 5.180 0.122 0.482 0.450 1.770 0.079 0.311 0.154 0.607
20 75 170 M T 0.338 1.281 1.255 4.752 0.117 0.444 0.470 1.780 0.106 0.402 0.488 1.848
20 75 168 M T 0.358 1.354 1.408 5.334 0.140 0.532 0.449 1.701 0.076 0.289 0.330 1.251
20 75 167 M T 0.358 1.419 1.408 5.588 0.118 0.466 0.399 1.584 0.108 0.427 0.102 0.406
8 23 498 M T 0.346 1.351 1.388 5.421 0.123 0.480 0.455 1.777 0.095 0.373 0.195 0.762
8 23 497 M T 0.328 1.225 1.445 5.393 0.131 0.490 0.406 1.515 0.115 0.430 0.060 0.224
8 23 496 M T 0.326 1.178 1.529 5.521 0.132 0.477 0.503 1.817 0.101 0.364 0.240 0.865
8 23 484 M T 0.312 1.191 1.376 5.251 0.125 0.479 0.385 1.469 0.133 0.506 0.152 0.581
9 23 102 M T 0.291 1.295 1.124 4.993 0.103 0.456 0.331 1.472 0.087 0.388 0.124 0.551
9 23 109 M T 0.351 1.394 1.126 4.467 0.116 0.461 0.421 1.670 0.055 0.216 0.322 1.277
9 23 115 M T 0.288 1.255 1.031 4.504 0.109 0.474 0.298 1.301 0.107 0.468 0.125 0.548
22 23 116 F C 0.244 1.038 1.134 4.825 0.095 0.403 0.373 1.585 0.104 0.441
22 23 119 F C 0.228 1.054 0.839 3.883 0.134 0.618 0.389 1.800 0.114 0.525
22 23 121 F C 0.229 1.155 0.798 4.029 0.103 0.519 0.290 1.466 0.130 0.655
21 75 101 F C 0.206 1.065 1.017 5.267 0.106 0.548 0.685 3.551 0.153 0.793
198 75 488 F C 0.187 0.951 0.985 5.002 0.109 0.553 0.342 1.738 0.066 0.337
198 75 490 F C 0.235 1.077 1.353 6.208 0.120 0.549 0.348 1.596 0.079 0.361
20 75 172 F T 0.246 1.143 1.192 5.546 0.116 0.539 0.324 1.506 0.102 0.473
20 75 169 F T 0.224 1.080 1.177 5.686 0.115 0.556 0.326 1.572 0.087 0.419
8 23 166 F T 0.199 1.025 1.125 5.801 0.099 0.512 0.326 1.679 0.074 0.381
8 23 165 F T 0.256 1.203 1.069 5.017 0.112 0.527 0.358 1.678 0.102 0.477
8 23 499 F T 0.242 1.143 1.102 5.197 0.107 0.506 0.322 1.517 0.078 0.367
8 23 483 F T 0.216 1.044 1.156 5.583 0.107 0.516 0.341 1.645 0.093 0.448
8 23 495 F T 0.229 1.095 1.093 5.227 0.103 0.494 0.300 1.436 0.078 0.374
8 23 486 F T 0.191 1.006 1.027 5.406 0.094 0.494 0.327 1.723 0.079 0.417
9 23 103 F T 0.208 1.119 0.990 5.325 0.093 0.501 0.259 1.392 0.098 0.528
9 23 104 F T 0.205 1.062 1.029 5.331 0.094 0.489 0.291 1.508 0.092 0.476
9 23 105 F T 0.208 1.089 0.793 4.150 0.111 0.579 0.295 1.543 0.083 0.434
9 23 107 F T 0.215 1.128 0.975 5.102 0.110 0.574 0.303 1.586 0.093 0.487
9 23 108 F T 0.223 1.072 0.798 3.836 0.107 0.513 0.278 1.338 0.095 0.454
9 23 110 F T 0.168 1.007 0.866 5.184 0.105 0.628 0.279 1.671 0.071 0.423
9 23 112 F T 0.216 1.078 0.985 4.923 0.104 0.518 0.327 1.637 0.070 0.349
9 23 113 F T 0.236 1.191 1.013 5.115 0.104 0.526 0.314 1.586 0.062 0.312
9 23 114 F T 0.199 1.080 0.836 4.542 0.116 0.629 0.309 1.679 0.117 0.636
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